Dedicated to Advancing the Clinical & Commercial Success of
Exosome Based Therapeutics
The exosome and EV-therapeutics industry is full of anticipation as the first few companies to reach clinical trials prepare to move ahead. As scientific understanding continues to grow and manufacturing methods constantly being fine-tuned, it’s now all about developing effective therapies to be the first to market.
The 2nd Digital Exosome Based Therapeutic Development Summit will unite pharma, biotech, academic and technology providers to accelerate the discovery, development and commercialization of safe and effective exosome-based therapeutics. Focusing exclusively on evidence-based therapeutic applications, this summit helps industry leaders and newcomers alike overcome key challenges to improve end-to-end development, inform therapeutic decision-making and progress robust pipelines in this exciting field.
How Will The Exosome Based Therapeutic Development Summit
Help You Develop Effective Therapeutic Candidates?
As the only industry-focused event specifically dedicated to the evidence-based development of exosome therapeutics, this is your platform to meet, connect and digitally network with pharma, biotech and technology experts from companies such as Evox Therapeutics, Capricor Therapeutics, Codiak Biosciences and ReNeuron to learn, debate and discuss to overcome your most pressing roadblocks.
Spanning 2 days, this digital meeting showcases the field’s most exciting breakthroughs to inform your discovery, manufacturing, commercial and regulatory strategies, expediting development timelines and enabling effective preclinical trials.
Why Should You Attend?
If you are exploring the therapeutic applications of exosomes in an evidence-based approach, this is the place for you.
This digital program is tailor-made to meet the industry’s biggest challenges, including scalable manufacturing, characterization, purification, cargo loading, understanding underlying mechanisms, and much more to empower teams to deliver GMP-grade targeted therapeutics.
Bringing together leading teams and newcomers alike, this conversation isn’t one to be missed.